HEALTH AND SOCIETY







Review Article

Information on lifestyle habits of individuals with COVID-19: Review of literature

Informações sobre hábitos de vida em indivíduos com COVID-19: Revisão da literatura

Información sobre los hábitos de vida de las personas con COVID-19 en todo el mundo: revisión de la literatura

https://doi.org/10.28998/rpss.e02106005

Received in: 04/24/2021 Accepted in: 05/25/2021 Available in: 06/15/2021

Corresponding Author:

Luiz carlos Francelino Silva junior

luizcfsj@gmail.com

Luiz Carlos Francelino Silva Junior¹ (0000-0002-9934-4174); Rafaela Campos Alcântara¹ (0000-0002-7956-4233); Gabriel Monteiro Arnozo¹ (0000-0001-8567-7085); Tatiana Farias de Oliveira¹ (0000-0002-4186-6287); Fernanda Mayara Santos Santana¹ (0000-0001-6920-937X); Etvaldo Rodrigues da Silva Filho¹ (0000-0001-7144-1709); Aisla Graciele Galdino dos Santos¹ (0000-0002-2119-3855); Euclides José Oliveira da Cunha¹ (0000-0002-8467-8657); Saulo Henrique Salgueiro de Aquino¹ (0000-0001-7458-1790); Rodrigo da Rosa Mesquita¹ (0000-0002-8212-4853); Gibson Barros de Almeida Santana (0000-0003-2443-720X); Antônio Leopoldo do Nascimento Gama Albuquerque (0000-0002-3047-1263)

Abstract

This is study sought to systematize information about life habits in epidemiological studies in patients with COVID-19. This is a systematic review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) recommendations. We selected articles published in PubMed, Medline and Scopus database between January 1 and April 24, 2020, using the descriptors COVID-19, SARS-CoV-2, 2019-nCoV, n-CoV and coronavirus combined with clinical profile and epidemiology. In this study, we sought to identify characteristics about patients' lifestyle habits: smoking (current or previous), alcohol consumption and physical activity. We analyzed 7489 scientific studies, of which 158 had clinical and epidemiological variables, amounting 100.563 patients. 30 studies included lifestyle habits (8,323 individuals) from five countries: Brazil, China, Korea, Spain and USA (593). A percentage of 56.5% (n = 4624) were men and 44.4% (n = 3687) women. Among the variables, smoking (current or previous) was present in 30 investigations; alcohol consumption in four and physical activity was not observed in any article. The highest smoking rates were observed in the USA (21.79%) and Spain (18.75%). Alcohol consumption was 7.73%. Being higher in Brazil (17.28%). New studies on the epidemiological and clinical aspects of COVID-19 include variables about lifestyle, especially smoking, alcohol consumption and physical activity. This information may offer future knowledge about the factors of illness and severity of COVID-19 in the population.

Descriptors: Risk factors. Coronavirus infection. Systematic review.

Resumo

Este estudo buscou sistematizar informações sobre hábitos de vida em estudos epidemiológicos em pacientes com COVID-19. Esta é uma revisão sistemática conduzida de acordo com as recomendações dos Itens de Relatório Preferenciais para Revisões Sistemáticas e Meta-análises (PRISMA). Selecionamos artigos publicados nas bases de dados PubMed, Medline e Scopus entre 1º de janeiro e 24 de abril de 2020, utilizando os descritores COVID-19, SARS-CoV-2, 2019-nCoV, n-CoV e coronavírus combinados com perfil clínico e epidemiologia. Neste estudo, buscou-se identificar características sobre os hábitos de vida dos pacientes: tabagismo (atual ou anterior), consumo de álcool e atividade física. Foram analisados 7.489 estudos científicos, dos quais 158 apresentavam variáveis clínicas e epidemiológicas, totalizando 100.563 pacientes. 30 estudos incluíram hábitos de vida (8.323 indivíduos) de cinco países: Brasil, China, Coréia, Espanha e EUA (593). Um percentual de 56,5% (n = 4624) eram homens e 44,4% (n = 3687) mulheres. Dentre as variáveis, o tabagismo (atual ou anterior) esteve presente em 30 investigações; consumo de álcool em quatro e atividade física não foi observada em nenhum artigo. As maiores taxas de tabagismo foram observadas nos EUA (21,79%) e na Espanha (18,75%). O consumo de álcool foi de 7,73%. Sendo maior no Brasil (17,28%). Novos estudos sobre os aspectos epidemiológicos e clínicos do COVID-19 incluem variáveis sobre estilo de vida, principalmente tabagismo, etilismo e atividade física. Essas informações podem oferecer conhecimento futuro sobre os fatores de doença e gravidade de COVID-19 na população. **Descritores**: Fatores de risco. Contágio do coronavírus. Revisão sistemática.

Resumen

Se trata de un estudio que busca sistematizar información sobre hábitos de vida en estudios epidemiológicos en pacientes con COVID-19. Esta es una revisión sistemática realizada de acuerdo con las recomendaciones de

¹ Departamento de Medicina, Universidade Federal de Alagoas, Arapiraca, Brasil.

² Servico de Atendimento Móvel de Urgência (SAMU), Arapiraca, Brasil.

Elementos de informe preferidos para revisiones sistemáticas y metaanálisis (PRISMA). Se seleccionaron los artículos publicados en la base de datos PubMed, Medline y Scopus entre el 1 de enero y el 24 de abril de 2020, utilizando los descriptores COVID-19, SARS-CoV-2, 2019-nCoV, n-CoV y coronavirus combinados con perfil clínico y epidemiología. En este estudio, buscamos identificar características sobre los hábitos de vida de los pacientes: tabaquismo (actual o previo), consumo de alcohol y actividad física. Se analizaron 7489 estudios científicos, de los cuales 158 tenían variables clínicas y epidemiológicas, totalizando 100,563 pacientes. Treinta estudios incluyeron hábitos de estilo de vida (8.323 personas) de cinco países: Brasil, China, Corea, España y EE. UU. (593). Un porcentaje del 56,5% (n = 4624) eran hombres y el 44,4% (n = 3687) mujeres. Entre las variables, el tabaquismo (actual o previo) estuvo presente en 30 investigaciones; en cuatro no se observó consumo de alcohol ni actividad física en ningún artículo. Las tasas de tabaquismo más altas se observaron en EE. UU. (21,79%) y España (18,75%). El consumo de alcohol fue del 7,73%. Siendo mayor en Brasil (17,28%). Los nuevos estudios sobre los aspectos epidemiológicos y clínicos de COVID-19 incluyen variables sobre estilo de vida, especialmente tabaquismo, consumo de alcohol y actividad física. Esta información puede ofrecer conocimientos futuros sobre los factores de la enfermedad y la gravedad de COVID-19 en la población.

Descriptores: Factores de riesgo. Infección de coronavirus. Revisión sistemática.

Introduction

In late 2019, an outbreak of pneumonia was observed in Wuhan, People's Republic of China ¹. On January 6, it was identified that the disease was caused by a new type of coronavirus, dubbed SARS-COV-2, causative agent of the COVID-19 disease ¹. Since then, COVID-19 has spread all over the continents, resulting in a pandemic, declared on March 11, 2020 by the World Health Organization (WHO) ².

In April 21, 2020, there were already over 2,5 million cases of COVID-19 around the globe and more than 175 thousand deaths due to the disease. The USA ranks first in confirmed cases (about 810 thousand) and Italy in number of deaths (about 24 thousand deaths). It should be noted that this scenario is still growing daily ³.

Faced with the new disease, scientists around the world have fought a real battle against time: on the one hand, a respiratory disease with a rapidly aggressive clinical pattern that results in failure of the respiratory function, resulting in the need for critical care; on another, scientists seeking to raise evidence that can assist health professionals in clinical decision-making and governments in the context of collective actions.

Among the evidence, the need to identify risk profiles, that increase the pathogenicity of the disease and the risk of death, emerges. Among the factors already known, previous comorbidities stand out, such as cardiovascular diseases (hypertension, diabetes, coronary heart disease). respiratory diseases (Obstructive Pulmonary Disease and asthma), immunosuppressants, cancer, transplant patients, among other complicating factors 4-5.

However, if the signs / symptoms, dissemination mechanisms, preventive measures and comorbidities are already known, the same is not true when it comes to life habits. It is not known, with due clarity, the prevalence of these lifestyle habits in hospitalized patients and their influence on the severity and clinical outcome of individuals infected with SARS-CoV-2.

Among the most common lifestyle habits, smoking, alcohol consumption and physical activity stand out. As a respiratory disease, it is likely that such habits may be related to the risk of illness and the severity of the symptons ⁶. However, the real effects of these habits have been little explored.

The first question to be answered is: "- Were the variables about lifestyle habits collected in studies involving patients with COVID-19?" If the answer is affirmative, a second must be answered: "- What is the prevalence of these habits?" Based on these questions, this study seeks to systematize the current literature on the life habits of patients hospitalized with COVID-19 in the world.

Methods

Data sources and Search strategies

This is a systematic review conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyzes (PRISMA) ⁷ recommendations and registered in the platform International Prospective Register of Systematic Reviews (PROSPERO), under the number 189122. The research question was: What is the prevalence of life habits in individuals hospitalized with COVID-19?

For the systematic review, we selected studies that address epidemiological characteristics of patients hospitalized with COVID-19. We selected articles published in PubMed, Medline and Scopus database between January 1 and April 24, 2020, using the descriptors COVID-19, SARS-CoV-2, 2019-nCoV, n-CoV and coronavirus combined with clinical profile and epidemiology. In this study, we sought to identify characteristics about patients' lifestyle habits: smoking (current or previous), alcohol consumption and physical activity. For the search strategy, the Boolean operators "AND" and "OR" were used. In addition, a manual search was carried out for references cited in the articles.

Research variables

In this study, we sought to identify characteristics about patients' lifestyle habits: smoking (current or previous), alcohol consumption and physical activity.

Eligibility criteria

We included clinical trials, cohorts, cross-sectional, clinical cases and case series studies(published and pre-print). Government epidemiological bulletins, comments, literature reviews, articles without full access to content and studies in animals were excluded.

Selection of studies

The search was carried out by four independent researchers. After this step, three researchers independently performed the following steps: 1- reading the title and summary to identify potential eligible studies; 2- reading the full text; 3- collection of variables and assembly of the database. The divergences were analyzed and resolved by consensus between the researchers.

Data extraction

For data extraction, the researchers created a database. The data was entered by a first investigator and subsequently checked by a second investigator on the team. The systematization / analysis of the data was conducted by two other independent researchers.

Results

Initially, 7489 scientific productions were found in the databases. Of these, 158 met the initial inclusion criteria and totaled 100.563 patients from all continents. After a complete reading, 30 studies [8-37] had variables on lifestyle habits, totaling 8323 patients from five countries (Figure 1, Table 1): Brazil (n = 81), China (7573), Korea (28), Spain (48) and USA (593). A percentage of 56.5% (n = 4624) were men and 44.4% (n = 3687) women. Among the variables, smoking (current or previous) was present in 29 investigations; alcohol consumption in four and physical activity was not observed in any article.




Figure 1- Flowchart of the study selection process, 2020.

Table 1- Characterization of the scientific articles included in the study.

Reference	Country	Population	Smoking	Alcohol consumption	Result
Borba et al. ⁸	Brazil	81	4	14	One current smoker was treated with a high dose of hydroxychloroquine and 8 among former smokers; among patients with high alcohol consumption, six used a high dose of hydroxychloroquine.
lan et al. 9	China	324	-	25	-
Chen et al. 10	China	99	2	-	Both smoking patiens passed away.
Yang et al. 11	China	52	2	-	Both smoking patients survived.
Chen et al. 12	China	29	2	-	-

Zhang et al. 13	China	140	2	-	6 patients were in serious health condition (4 ex smokers:, 2 current smokers).
Li et al. 14	China	17	3	3	Among smokers, 2 patients were discharged as well as 1 alcoholic patient.
Song et al. 15	China	51	3	-	-
Huang et al. 16	China	41	3	-	Smoking patients did not need ICU care.
Wang et al. 17	China	26	5	-	-
Zhang et al. 18	China	120	6	-	All 6 smokers were complicated cases of Covid-19.
Zhou et al. 19	China	191	11	-	5 (45.45%) of the total smoking patients did not survive.
Wang et al. ²⁰	China	125	16	-	Among the 25 critical patients, 7 (28%) were smokers. History of smoking was statistically significant, and may be a risk factor for poor prognosis, especially in poor populations.
Guo et al. ²¹	China	187	18	-	Smoking rate did not differentiate between patients with elevated or normal troponin T.
Ji et al. ²²	China	202	19	6	Alcohol consumption and smoking were not statistically associated with covid-19 progression.
Liu et al. 23	China	56	22	-	-
Shi et al. 24	China	487	40	-	34 (7.8%) of mild cases and 6 (12.2%) of severe cases were smokers
Li et al. 25	China	548	41	-	About 19.2% of critically ill patients were smokers.
Jin et al. 26	China	651	41	-	-
Feng et al. ²⁷	China	476	44	37	Among the 68 critical cases, 10 (14.7%) had a history of smoking and 11 (16.2%) had a history of alcohol consumption.
Lian et al. ²⁸	China	788	54	-	Proportional prevalence of smokers < 60 years old. There was no significant correlation with covid-19 symptoms.
Liang et al. 29	China	1590	111	-	-
Guan et al. 30	China	1099	137	-	16.9% of covid-19 severe cases were smoking patients.
Chen et al. 31	China	274	19	-	Smoking patients represented 8% of the total number of deaths.
Kim et al. 32	Korea	28	5	-	60% of smoking patients had pneumonia, 40% with bilateral presentation.
Barrasa et al. 33	Spain	48	9	-	19% of cases were associated with Procalcitonin levels> 0.5 μg / L, presenting a 16% higher risk of death in 7 days.
Moein et al. 34	USA	60	2	-	Control cohort had many more smoking patients, study suggests protection of the host against lung injury.
Cholankeril et al.	USA	116	3	-	94.8% of the evaluated patients presented with cough.
Bhatraju et al. ³⁶	USA	24	5	-	Only half of the patients had fever at the time of hospital admission. Data on current or previous cigarette consumption from 1 patient was missing.

Goyal et al. 37 USA

393

20

4.6% of smoking patients required invasive mechanical ventilation.

The study population with the variable tobacco consumption was 7999. Among these, the smoking rate was 8.1% (n = 648) considering current consumption and 10.46% (n = 837), including ex-smokers. The highest smoking rates were observed in the USA (21.79%) and Spain (18.75%). The sum of the population of the five

articles with information about alcohol consumption was 1100, of which alcohol consumption was observed in 85 (7.73%). Alcohol consumption was higher in Brazil (17.28%) (Table 2).

Table 2- Smoking and alcohol consumption in hospitalized patients with COVID-19, 2020.

a) Smoking						
Country	Number of studies	Number of patients	Current smokers	Ex-smokers	Overall rate (%)	
Brazil	1	81	4	11	18.51	
China	22/23 ¹	7249	600	79	9.36	
Korea	01	28	5	-	17.86	
Spain	01	48	9	-	18.75	
ÚSA	04	593	30	99	21.75	
Total	29	7999	648	189	10.46	

	b) Alconol Consumption						
Country	Number of studies	Number of patients	Alcohol consumption	Overall rate (%)			
China	3	695	71	10.22			
Brazil	1	81	14	17.28			
Total	4	776	85	10.95			

Legend: 101 report did not present data about smoking.

Discussion

Cigarette consumption was the most observed theme among lifestyle habits in the researched studies. SARS-CoV-2 penetrates the cell of the epithelial and alveolar mucosa of the lung using the ACE-2 receptor and it is known that this mucosa is damaged by the substances present in cigarettes, suggesting greater severity of the disease in smokers when compared to non-smokers ³⁸⁻³⁹. Additionally, the act of smoking itself could operate as a virus carrier for the face, increasing the risk of contamination ⁴⁰.

During the pandemic, social isolation and the rise in individuals' level of psychological stress has been an additional concern. This context changes the lifestyle of

the population, limiting the practice of physical activity and increasing the risk of adopting less healthy habits, such as alcohol consumption, smoking and unbalanced diet. Individuals who face or have faced problems with alcohol or cigarette consumption tend to relapse in the face of moments of anxiety and stress, such as the current one ^{6, 41}.

In another part of the population, in turn, fear of the virus and its consequences have the opposite effect. As it is a disease that can presents with severe impairment of pulmonary and cardiac functions and, knowing the deleterious effects of smoking, they have adopted an attitude of interrupting cigarette consumption ⁴¹.

In recent years, WHO and member countries have been engaged in the fight against smoking, with satisfactory results. Even so, in 2018, only 23 countries implemented mechanisms to support individuals who wish to guit smoking. China, the first epicenter of the Covid-19 pandemic, is the world's largest tobacco consumer. About 22% of the population actively smokes and tobacco causes about 1 million deaths of smokers as well as about 100,000 deaths in passive smokers, each year 42. In the USA, the country with the highest number of registered cases, there was a recent explosion in the consumption of electronic cigarettes among young people, rising from 1.5% in 2011 to 20.8% in 2018 44. In Brazil, on the other hand, the path is reversed, even though still far from ideal. The proportion of adult smokers decreased from 35% in 1989 to 18.5% in 2008. In 2017, the prevalence of smoking was 11% 45. In adolescents, this rate was around 17%, according to data from the Education at School Program (PSE), in 2015 44.

Although tobacco consumption is the most prominent element, it is necessary to highlight alcohol consumption. In the human body, alcohol reduces the synthesis of albumin, serum concentrations of magnesium, calcium and phosphate, increasing lactate and ketone, as well as oxygen ⁴⁶. In these individuals, the incidence of sepsis, especially of respiratory origin, is higher than in the general population ⁴⁷. There is still insufficient evidence to indicate the effects of alcohol consumption on the spread and severity of SARS-CoV-2.

Conclusions

Finally, the practice of physical activity, not observed in any study, represents a knowledge gap to be filled. We recommend that new studies on the epidemiological and clinical aspects of COVID-19 include variables about lifestyle, especially smoking, alcohol consumption and physical activity. This information may offer future knowledge about the factors of illness and severity of COVID-19 in the population. In addition, studies are still much concentrated in China, requiring research with other population profiles.

References

- 1- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med [Internet]. 2020 [cited 2020Apr28];382(8):727–33. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2001017.
- 2- World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report 51. 2020 [cited 2020 Abr 03]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10.
- 3- COVID-19 Map [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2020Apr28]. Available from: https://coronavirus.jhu.edu/map.html.
- 4- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020Mar1 [cited 2020Apr28];395(10229):1054–62. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext.
- 5- Tan W, Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol [Internet]. 2020Mar28 [cited 2020Apr28];309:70–7. Available from: https://www.internationaljournalofcardiology.com/article/S0167-5273(20)31593-X/fulltext.
- 6- Simons D, Perska O, Brown J. Covid-19: The role of smoking cessation during respiratory virus epidemics [Internet]. BMJ Open. 2020 [cited 2020Apr28]. Available from: https://blogs.bmj.com/bmj/2020/03/20/covid-19-the-role-of-smoking-cessation-during-respiratory-virus-epidemics/.
- 7- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA. Statement. PLoS Med 2009 6(7): e1000097. doi:10.1371/journal.pmed1000097
- 8- Borba MGS, Val FDA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). Medrxiv [Internet]. 2020Apr16 [cited 2020Apr28]; Available from: https://www.medrxiv.org/content/10.1101/2020.04.07.20056424v2.full.p.gdf

- 9- Ian ZP, Mei X, Zhang YY, Zou Y, Zhang ZG, Zhu H et al. Analysis of baseline liver biochemical parameters in 324 cases with novel coronavirus pneumonia in Shanghai area. Zhonghua gan Zang Bing za zhi= Zhonghua Ganzangbing Zazhi= Chinese Journal of Hepatology 2020; 28, E005-E005. Avaliable from http://rs.yiigle.com/yufabiao/1188686.htm
- 10- Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020 Jan 30 [cited 2020Apr28];395(10223):507–13. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30211-7/fulltext
- 11- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet [Internet]. 2020 Feb 24 [cited 2020 Apr 28. Available from:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30079-5/fulltext

- 12- Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He Hu Xi Za Zhi. 2020 feb 06. Available from: http://rs.yiigle.com/yufabiao/1180104.htm
- 13- Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS- CoV- 2 in Wuhan, China. Allergy [Internet]. 2020Feb19 [cited 2020Apr28]; Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/all.14238
- 14- Li J, Li S, Cai Y, Liu Q, Li X, Zeng Z, et al. Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China. Medrxiv [Internet]. 2020 Feb 12; Available from: https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1
- 15- Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology [Internet]. 2020Feb6 [cited 2020Apr28];295(1):210–7. Available from: https://pubs.rsna.org/doi/10.1148/radiol.2020200274?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed
- 16- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020Jan24 [cited 2020Apr28];395(10223):497–506. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext
- 17- Wang L, Duan Y, Zhang W, Liang J, Xu J, Zhang Y, et al. Epidemiologic and Clinical Characteristics of 26 Cases of COVID-19 Arising from Patient-to-Patient Transmission in Liaocheng, China. J Clin Epidemiol [Internet]. 2020Apr9 [cited 2020Apr28];Volume 12:387–91. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154005/
- 18- Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. Eur Radiol 2020Apr11;:1–10.
- 19- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020Mar28 [cited 2020Apr28];395(10229):1054–62. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext
- 20- Wang R, Pan M, Zhang X, Fan X, Han M, Zhao F, et al. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis [Internet]. 2020Apr11 [cited 2020Apr28]; Available from: https://www.ijidonline.com/article/S1201-9712(20)30203-4/fulltext
- 21- Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020Mar27 [cited

- 2020Apr28]; Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2763845
- 22- Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol [Internet]. 2020Apr8 [cited 2020Apr28]; Available from: https://www.journal-of-hepatology.eu/article/S0168-8278(20)30206-3/fulltext
- 23- Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect [Internet]. 2020Mar11 [cited 2020Apr28]; Available from: https://www.journalofinfection.com/article/S0163-4453(20)30116-X/fulltext
- 24- Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care [Internet]. 2020Mar18 [cited 2020Apr28];24(1). Available from: https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-2833-7
- 25- Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol [Internet]. 2020Apr12 [cited 2020Apr28]; Available from: https://www.jacionline.org/article/S0091-6749(20)30495-4/pdf
- 26- Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut [Internet]. 2020Mar24 [cited 2020Apr28]; Available from: https://gut.bmj.com/content/early/2020/03/24/gutjnl-2020-320926.long
- 27- Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med [Internet]. 2020Apr10 [cited 2020Apr28]; Available from: https://www.atsjournals.org/doi/abs/10.1164/rccm.202002-0445OC
- 28- Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of Epidemiological and Clinical Features in Older Patients With Coronavirus Disease 2019 (COVID-19) Outside Wuhan. Clin Infect Dis [Internet]. 2020Mar25; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa242/5811557
- 29- Liang W-H, Guan W-J, Li C-C, Li Y-M, Liang H-R, Zhao Y, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J [Internet]. 2020Apr8 [cited 2020Apr28]; Available from: https://erj.ersjournals.com/content/early/2020/04/01/13993003.00562-2020
- 30- Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020Feb28 [cited 2020Apr28]; Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2002032
- 31- Chen T et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. [Internet]. 2020;368:m1091. Avaliable from: https://www.bmj.com/content/368/bmj.m1091.doi.org/10.1136/bmj.m1091
- 32- Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi J-P, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. J Korean Med Sci [Internet]. 2020Apr6 [cited 2020Apr28];35(13). Available from: https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e142
- 33- Barrasa H, Rello J, Tejada S, Martín A, Balziskueta G, Vinuesa C, et al. SARS-Cov-2 in Spanish Intensive Care: Early Experience with 15-day Survival In Vitoria. Anaesth Crit Care Pain Med [Internet]. 2020Apr9 [cited 2020Apr28]; Available from: https://www.sciencedirect.com/science/article/pii/S2352556820300643? via=ihub
- 34- Moein ST, Hashemian SM, Mansourafshar BL, Khorram-Tousi Aundefined, Tabarsi Pundefined, Doty Rundefined. Smell dysfunction: a

biomarker for COVID- 19. International Forum of Allergy & Rhinology [Internet]. 2020Apr17 [cited 2020Apr28]; Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/alr.22587

- 35- Cholankeril G, Podboy A, Aivaliotis VI, Tarlow B, Pham EA, Spencer S, et al. High Prevalence of Concurrent Gastrointestinal Manifestations in Patients with SARS-CoV-2: Early Experience from California. Gastroenterology [Internet]. 2020Apr10 [cited 2020Apr28]; Available from: https://www.ncbi.nlm.nih.gov/
- 36- Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically III Patients in the Seattle Region Case Series. New England Journal of Medicine [Internet]. 2020Mar30 [cited 2020Apr28]; Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2004500
- 37- Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical Characteristics of Covid-19 in New York City. New England Journal of Medicine [Internet]. 2020Apr17 [cited 2020Apr28]; Available from: https://www.nejm.org/doi/full/10.1056/NEJMc2010419
- 38- Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020Feb3 [cited 2020Apr28];579(7798):270–3. Available from: https://www.nature.com/articles/s41586-020-2012-7.
- 39- Hamm JT, Yee S, Rajendran N, Morrissey RL, Richter SJ, Misra M. Histological Alterations in Male A/J Mice Following Nose-Only Exposure to Tobacco Smoke. Inhal. Toxicol [Internet]. 2007 [cited 2020Apr28];19(5):405–18. Available from: https://www.tandfonline.com/doi/full/10.1080/08958370601174875.
- 40- özlu T, çelik I, öztuna F, Bülbül Y, özsu şavas. Streptococcus pneumoniae Adherence in Rats under Different Degrees and Durations of Cigarette Smoke. Respiration [Internet]. 2008Mar [cited 2020Apr28];75(3):339–44. Available from: https://www.karger.com/Article/Abstract/112472
- 41- Stubbs B, Veronese N, Vancampfort D, Prina AM, Lin P-Y, Tseng P-T, et al. Perceived stress and smoking across 41 countries: A global perspective across Europe, Africa, Asia and the Americas. Sci Rep (Nat Publ Group). 2017Aug8;7(1). Available from: https://www.nature.com/articles/s41598-017-07579
- 42- Iglesias RM. Increasing excise taxes in the presence of an illegal cigarette market: the 2011 Brazil tobacco tax reform. Rev Panam Salud Publica 2016; 40(4):243-249. Available from: https://www.scielosp.org/pdf/rpsp/2016.v40n4/243-249
- 43- Gan Q, Hammond SK, Jiang Y, Yang Y, Hu T-W. Effectiveness of a Smoke-Free Policy in Lowering Secondhand Smoke Concentrations in Offices in China. J Occup Environ Med [Internet]. 2008May;50(5):570–5. Available from:

https://journals.lww.com/joem/Abstract/2008/05000/Effectiveness_of_a_Smoke_Free_Policy_in_Lowering.7.aspx?trendmd-shared=0

- 44- Cullen KA, Ambrose BK, Gentzke AS, Apelberg BJ, Jamal A, King BA. Notes from the Field: Use of Electronic Cigarettes and Any Tobacco Product Among Middle and High School Students United States, 2011–2018. MMWR Morb Mortal Wkly Rep [Internet]. 2018Nov16 [cited 2020Apr28];67(45):1276–7. Available from: https://www.cdc.gov/mmwr/volumes/67/wr/mm6745a5.htm?scid=mm6745a5 w
- 45- Portes LH, Machado CV, Turci SRB, Figueiredo VC, Cavalcante TM, Vera Luiza Da Costa E Silva. A Política de Controle do Tabaco no Brasil: um balanço de 30 anos. Cien Saude Colet [Internet]. 2018Jun6 [cited 2020Apr28];23(6):1837–48. Available from: http://www.scielo.br/scielo.php?script=sci arttext&pid=S1413-81232018000601837&Ing=en
- 46- Hämäläinen MD, Zetterström A, Winkvist M, Söderquist M, Öhagen P, Andersson K, et al. Breathalyser-Based eHealth Data Suggest That Self-Reporting of Abstinence Is a Poor Outcome Measure for Alcohol Use Disorder Clinical Trials. Alcohol Clin Exp res. [Internet]. 2020Apr3 [cited 2020Apr28];55(3):237–45. Available from: https://academic.oup.com/alcalc/article-abstract/55/3/237/5770901?redirectedFrom=fulltext

47- Fernández MS, Bellia F, Ferreyra A, Chiner F, García AMJ, D'Addario C, et al. Short-term selection for high and low ethanol intake during adolescence exerts lingering effects in stress-induced ethanol drinking and yields an anxiety-prone phenotype. Behav Brain Res [Internet]. 2020Feb17 [cited 2020Apr28];380:112445. Available from: https://www.sciencedirect.com/science/article/pii/S0166432819316900? via=ihub

Cite:

Silva Jr, Alcântara RC, Arnozo GM, et al. Information on lifestyle habits of individuals with COVID-19 worldwide: Review of literature. Rev. Port. Saúde e Sociedade. 2021;6(único):e02106005. Doi:10.28998/rpss.e02106005.